<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58409">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02345642</url>
  </required_header>
  <id_info>
    <org_study_id>14064</org_study_id>
    <nct_id>NCT02345642</nct_id>
  </id_info>
  <brief_title>A Hemodynamic Comparison of Stationary and Portable Pneumatic Compression Devices</brief_title>
  <official_title>A Hemodynamic Comparison of Stationary and Portable Pneumatic Compression Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DJO Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are comparing two pneumatic compression devices, VenaFlow (stationary) and MCS (portable)
      in both the supine an standing position. We will start supine and will take 3 baseline
      measurements of venous velocity and then apply a device and take 3 measurements of the
      increase in peak venous velocity. We will repeat this with the second device. We will then
      have the subject stand and repeat the above with each device. We will randomize the order of
      the devices in the supine and standing position. This study will involve 10 healthy subjects
      of various ages and 10 THR patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Venous Velocity</measure>
    <time_frame>30 minutes</time_frame>
    <description>Ultrasound of the venous system just below the saphenofemoral junction to assess the venous velocity will be taken before and after application the VenaFlow and the ActiveCare+S.F.T pneumatic compression devices. PVV will be recorded at baseline and then after each device is applied.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Total Hip Arthroplasty</condition>
  <arm_group>
    <arm_group_label>10 Healthy Patients without THA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The 10 test subjects of this study arm will be healthy volunteers of various ages that are willing to have the efficacy of pneumatic compression tested on them.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 Patients with THA on Post-Op Day 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 10 test subjects of this study arm will be primary THR patients of Dr. Westrich that have undergone uncomplicated THR surgery in which they are allowed to be full weight bearing by or before post-op day 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ActiveCare+SFT Supine</intervention_name>
    <arm_group_label>10 Healthy Patients without THA</arm_group_label>
    <arm_group_label>10 Patients with THA on Post-Op Day 2</arm_group_label>
    <other_name>Portable Pneumatic Compression Device Supine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VenaFlow Elite Supine</intervention_name>
    <arm_group_label>10 Healthy Patients without THA</arm_group_label>
    <arm_group_label>10 Patients with THA on Post-Op Day 2</arm_group_label>
    <other_name>Stationary Pneumatic Compression Device Supine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ActiveCare+SFT Standing</intervention_name>
    <arm_group_label>10 Healthy Patients without THA</arm_group_label>
    <arm_group_label>10 Patients with THA on Post-Op Day 2</arm_group_label>
    <other_name>Portable Pneumatic Compression Device Standing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VenaFlow Elite Standing</intervention_name>
    <arm_group_label>10 Healthy Patients without THA</arm_group_label>
    <arm_group_label>10 Patients with THA on Post-Op Day 2</arm_group_label>
    <other_name>Stationary Pneumatic Compression Device Standing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Phase one: 10 healthy test subjects will be included of various ages. They will have each
        pneumatic compression device applied in the supine and then standing positions.

        Phase two: 10 patients following THR on postoperative day #2 will be included. These
        patients will agree to participate in the study and have to be able to stand for
        approximately 10 minutes.

        Exclusion Criteria:

          -  Patients with lymphedema

          -  Patients with peripheral vascular disease (chronic venous insufficiency)

          -  Patients who do not wish to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucian Warth, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.djoglobal.com/products/venaflow/venaflow-elite-system</url>
    <description>VenaFlow Elite Description on DJO Global's website</description>
  </link>
  <link>
    <url>http://www.mcsmed.com/activecare_sft_2.html</url>
    <description>ActiveCare+SVT Description on MCS's website</description>
  </link>
  <reference>
    <citation>Westrich GH, Specht LM, Sharrock NE, Windsor RE, Sculco TP, Haas SB, Trombley JF, Peterson M. Venous haemodynamics after total knee arthroplasty: evaluation of active dorsal to plantar flexion and several mechanical compression devices. J Bone Joint Surg Br. 1998 Nov;80(6):1057-66.</citation>
    <PMID>9853503</PMID>
  </reference>
  <reference>
    <citation>Westrich GH, Specht LM, Sharrock NE, Sculco TP, Salvati EA, Pellicci PM, Trombley JF, Peterson M. Pneumatic compression hemodynamics in total hip arthroplasty. Clin Orthop Relat Res. 2000 Mar;(372):180-91.</citation>
    <PMID>10738427</PMID>
  </reference>
  <reference>
    <citation>Johanson NA, Lachiewicz PF, Lieberman JR, Lotke PA, Parvizi J, Pellegrini V, Stringer TA, Tornetta P 3rd, Haralson RH 3rd, Watters WC 3rd. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Am Acad Orthop Surg. 2009 Mar;17(3):183-96.</citation>
    <PMID>19264711</PMID>
  </reference>
  <reference>
    <citation>Pitto RP, Hamer H, Heiss-Dunlop W, Kuehle J. Mechanical prophylaxis of deep-vein thrombosis after total hip replacement a randomised clinical trial. J Bone Joint Surg Br. 2004 Jul;86(5):639-42.</citation>
    <PMID>15274256</PMID>
  </reference>
  <reference>
    <citation>Ben-Galim P, Steinberg EL, Rosenblatt Y, Parnes N, Menahem A, Arbel R. A miniature and mobile intermittent pneumatic compression device for the prevention of deep-vein thrombosis after joint replacement. Acta Orthop Scand. 2004 Oct;75(5):584-7.</citation>
    <PMID>15513491</PMID>
  </reference>
  <reference>
    <citation>Froimson MI, Murray TG, Fazekas AF. Venous thromboembolic disease reduction with a portable pneumatic compression device. J Arthroplasty. 2009 Feb;24(2):310-6. doi: 10.1016/j.arth.2007.10.030.</citation>
    <PMID>18534456</PMID>
  </reference>
  <reference>
    <citation>Murakami M, McDill TL, Cindrick-Pounds L, Loran DB, Woodside KJ, Mileski WJ, Hunter GC, Killewich LA. Deep venous thrombosis prophylaxis in trauma: improved compliance with a novel miniaturized pneumatic compression device. J Vasc Surg. 2003 Nov;38(5):923-7.</citation>
    <PMID>14603195</PMID>
  </reference>
  <reference>
    <citation>Colwell CW Jr, Spiro TE, Trowbridge AA, Morris BA, Kwaan HC, Blaha JD, Comerota AJ, Skoutakis VA. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am. 1994 Jan;76(1):3-14. Erratum in: J Bone Joint Surg Am 1994 Mar;76(3):4741.</citation>
    <PMID>8288662</PMID>
  </reference>
  <reference>
    <citation>Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW; American College of Chest Physicians.. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):381S-453S. doi: 10.1378/chest.08-0656.</citation>
    <PMID>18574271</PMID>
  </reference>
  <reference>
    <citation>Silbersack Y, Taute BM, Hein W, Podhaisky H. Prevention of deep-vein thrombosis after total hip and knee replacement. Low-molecular-weight heparin in combination with intermittent pneumatic compression. J Bone Joint Surg Br. 2004 Aug;86(6):809-12.</citation>
    <PMID>15330019</PMID>
  </reference>
  <reference>
    <citation>Edwards JZ, Pulido PA, Ezzet KA, Copp SN, Walker RH, Colwell CW Jr. Portable compression device and low-molecular-weight heparin compared with low-molecular-weight heparin for thromboprophylaxis after total joint arthroplasty. J Arthroplasty. 2008 Dec;23(8):1122-7. doi: 10.1016/j.arth.2007.11.006.</citation>
    <PMID>18534421</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>June 9, 2016</lastchanged_date>
  <firstreceived_date>January 20, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital for Special Surgery, New York</investigator_affiliation>
    <investigator_full_name>Geoffrey Westrich</investigator_full_name>
    <investigator_title>Professor of Clinical Orthopaedic Surgery</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
